Analytical Data
-
Gene name
EBNA2
- Application
-
Alternative Names
EBNA2; BYRF1Epstein-Barr nuclear antigen 2; EBNA-2; EBV nuclear antigen 2
-
Species
Epstein-Barr virus
-
Source
Yeast
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q69022
-
Expression Region
247-454aa
-
Molecular Weight
25.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EBNA2 (Epstein-Barr virus Nuclear Antigen 2) is a critical protein involved in the pathogenesis of Epstein-Barr virus (EBV), which is linked to various lymphoproliferative disorders and lymphomas. EBV, a member of the herpesvirus family, is one of the most common human viruses, and its association with diseases such as infectious mononucleosis and several types of cancer has garnered significant research interest. EBNA2 plays a pivotal role in the transformation of B lymphocytes, promoting cell proliferation and survival by activating several cellular genes. Its mechanism of action involves interaction with host cell transcription factors, leading to altered gene expression and oncogenic potential. The study of EBNA2 is crucial for understanding the molecular pathways underlying EBV-related malignancies and for developing targeted therapies. Recent advancements in recombinant protein technology have allowed for the production and characterization of EBNA2 in vitro, facilitating studies on its functional properties and interactions. By elucidating the structure and function of EBNA2, researchers aim to identify potential biomarkers for disease progression and therapeutic targets, thereby contributing to the broader field of viral oncology. As the global burden of EBV-associated diseases continues to rise, increasing our understanding of EBNA2's role in these processes is essential for developing novel strategies for intervention and treatment.
